comparemela.com

(Reuters) -The U.S. Food and Drug Administration on Friday allowed the use of Bristol-Myers Squibb and 2seventybio's cell therapy Abecma in less severely affected patients with a type of blood cancer. The decision comes after a panel of expert advisers...

Related Keywords

Bengaluru ,Karnataka ,India ,Sriparna Roy ,Bhanvi Satija ,Bristol Myers Squibb ,Reuters ,Drug Administration On ,Johnson ,Drug Administration ,Legend Biotech ,Sriraj Kalluvilaand Krishna Chandra Eluri ,

© 2025 Vimarsana

comparemela.com © 2020. All Rights Reserved.